{"filing":{"accession_number":"0001193125-26-381076","cik":"0001691082","ticker":"LBRX","company_name":"LB PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-09-03","report_date":"2026-09-03","primary_document":"d26110d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526381076/d26110d8k.htm"},"events":[{"id":31485,"run_id":28892,"accession_number":"0001193125-26-381076","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Joseph M. Miller has been appointed as Chief Financial Officer of LB Pharmaceuticals effective September 2, 2026. The appointment includes compensatory arrangements comprising a base salary of $530,000, a target bonus of 40%, and an equity option grant of 200,000 shares. Miller brings extensive biopharmaceutical finance experience and will support the company through a potentially transformative period including pivotal clinical trial results and potential commercialization of LB-102.","company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","filing_date":"2026-09-03","form":"8-K","submitted_at":null,"items":[{"id":34380,"accession_number":"0001193125-26-381076","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Joseph M. Miller has been appointed as Chief Financial Officer of LB Pharmaceuticals effective September 2, 2026. The disclosure centers on the appointment of a named executive officer to a principal financial role, with detailed background on his qualifications and experience. While the filing also includes compensatory arrangements (base salary of $530,000, target bonus of 40%, and equity option grant of 200,000 shares), the principal disclosed action is the appointment itself, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T12:06:05.482680+00:00","company_name":"","ticker":null,"filing_date":""},{"id":34381,"accession_number":"0001193125-26-381076","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure announces the appointment of Joseph Miller as Chief Financial Officer of LB Pharmaceuticals, effective September 3, 2026. This is a clear executive appointment of a named officer to a C-suite position. The press release emphasizes Miller's extensive biopharmaceutical finance experience and his role in supporting the company through a \"potentially transformative period\" including pivotal clinical trial results and potential commercialization of LB-102, making this material to investors' assessment of the company's leadership and operational readiness.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T12:06:05.482680+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34380,"accession_number":"0001193125-26-381076","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Joseph M. Miller has been appointed as Chief Financial Officer of LB Pharmaceuticals effective September 2, 2026. The disclosure centers on the appointment of a named executive officer to a principal financial role, with detailed background on his qualifications and experience. While the filing also includes compensatory arrangements (base salary of $530,000, target bonus of 40%, and equity option grant of 200,000 shares), the principal disclosed action is the appointment itself, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T12:06:05.482680+00:00","company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","filing_date":"2026-09-03"},{"id":34381,"accession_number":"0001193125-26-381076","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure announces the appointment of Joseph Miller as Chief Financial Officer of LB Pharmaceuticals, effective September 3, 2026. This is a clear executive appointment of a named officer to a C-suite position. The press release emphasizes Miller's extensive biopharmaceutical finance experience and his role in supporting the company through a \"potentially transformative period\" including pivotal clinical trial results and potential commercialization of LB-102, making this material to investors' assessment of the company's leadership and operational readiness.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T12:06:05.482680+00:00","company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","filing_date":"2026-09-03"}]}